Fasidotril Eli Lilly.

Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.
AuthorsFatih Ozdener, Vural Ozdemir
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 9 Pg. 1113-9 (Sep 2003) ISSN: 1472-4472 [Print] England
PMID14582457 (Publication Type: Journal Article, Review)
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Protease Inhibitors
  • aladotril
  • Alanine
  • Alanine (administration & dosage, analogs & derivatives, chemistry, therapeutic use)
  • Angiotensin-Converting Enzyme Inhibitors (administration & dosage, chemistry, therapeutic use)
  • Antihypertensive Agents (administration & dosage, chemistry, therapeutic use)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Heart Failure (drug therapy, enzymology)
  • Humans
  • Hypertension, Renovascular (drug therapy, enzymology)
  • Molecular Structure
  • Protease Inhibitors (administration & dosage, chemistry, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: